Latest Blogs

Guest Commentary
Nov 28, 2023
Women Mentoring Women: A Thank You Note to My Two Heroes
Dr. Tara Rajendran honors two women who, through their kindness and thoughtful attention, shaped her professional path from an early age.
Linda R. Duska, MD, MPH
Nov 20, 2023
The Potential of AI in Clinical Research
"We all need to stay informed and engaged on the topic of AI in order to be the best advocates for ourselves, our profession, and our patients."
International Perspectives
Nov 03, 2023
Cancer, Conflict, and Catastrophe: A Cry for Help From Sudan, a Country at War
Millions of people have been affected by the war in Sudan, and the outlook for patients with cancer is particularly dire. Dr. Nabeeha Karadawi, Dr. Salma Awad Elkareem Ali Mohamed, and Nagham Ali outline the current situation and call for immediate international aid.
Abdul-Rahman Jazieh, MD, MPH
Oct 24, 2023
Should Oncologists Continue to Be Ambivalent About Dietary Supplement Use by Their Patients?
If we believe that dietary supplements are active compounds—and many are—then we should deal with them as medications and advise our patients accordingly.
Subscribe to this column

Edward P. Balaban, FACP, DO, FASCO

Edward P. Balaban, DO, FACP, FASCO, is the medical director for the Cancer Care Partnership with Penn State University Cancer Institute and professor of medicine at Penn State Hershey Cancer Institute. He has served as a Practice Guideline Implementation Network (PGIN) representative for Weight-Based Dosing Chemotherapy for Cancer Patients and Gastrointestinal Guideline Advisory Groups. Dr. Balaban is past president of the Pennsylvania Society of Oncology and Hematology. He serves as an ASCO delegate to the American Medical Association House of Delegates (AMA HOD).

Disclosure.

Jun 22, 2016
So Much Done, So Much More to Do: AMA House of Delegates Report
ASCO composed and successfully brought to the AMA-HOD several resolutions representing some of our most pressing concerns and/or initiatives, including regulations on handling hazardous materials, transparency on clinical pathways, reimbursement models, and Part B drug payments.
Jan 05, 2016
AMA House of Delegates: A Glimpse into the Future
ASCO staff and  member representatives gathered in Atlanta for the AMA House of Delegates' recent meeting, and, as usual, listened, learned, and spoke on a number of topics.
Jun 18, 2015
It’s Good to Grow—with the AMA-HOD
The AMA House of Delegates (AMA-HOD) convened a few days after the ASCO Annual Meeting.  It was, in many ways, a continuation of many of the concerns reviewed at the annual ASCO gathering. The delegation representing ASCO is now composed of ASCO staff, along with Drs. Thomas Marsland, Ray Page,...
Jun 01, 2015
Much To Do and More To Come
The annual ASCO gathering is now in its last 48 hours, and it has been interesting. I have heard discussions concerning payment reform, oncology medical homes, and value based care. The highlighted plenary presentations concerning what appears to be a major clinical advance in the treatment of...
Nov 25, 2014
The AMA House of Delegates Update: “And in the End. . . ”
The American Medical Association House of Delegates (AMA HOD) met once again last week in Dallas, Texas. This was the interim meeting where we welcomed ASCO’s new alternate delegate Dr. Kristina Maletz. As always, a wide variety of reports and resolutions were proposed. ...
Jun 26, 2014
The AMA House of Delegates: We Have a Lot to Discuss
We just returned from the American Medical Association (AMA) House of Delegates (HOD) gathering. Once again, it proved to be extensive, revealing, and eventful. ASCO’s Dr. Barbara McAneny was reelected to the AMA...

Pages